House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Hepatology

Liver: Acute Liver Failure

ACG · 2023 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

Acute liver failure is a medical emergency requiring simultaneous cause identification, organ support and early transplant-centre involvement. This ACG guideline distinguishes acute liver failure from decompensated cirrhosis and acute-on-chronic failure, whose management differs. Much of the evidence is observational or expert consensus, so recommendations and uncertain practices should not be treated as equally established.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognize the syndrome and refer early

  • Suspect acute liver failure with illness lasting less than 26 weeks, encephalopathy and INR ≥1.5, generally without pre-existing liver disease. Autoimmune hepatitis, Budd–Chiari syndrome and Wilson disease may present acutely despite advanced fibrosis; distinguish this syndrome from acute-on-chronic failure. [1]
  • Establish the symptom timeline and assess prior liver disease, alcohol exposure, viral risks, prescription drugs, over-the-counter products and supplements. Obtain collateral history when the patient cannot provide it, and perform comprehensive testing to identify the cause and exclude chronic disease. [1]
  • Contact hepatology or gastroenterology promptly and communicate early with a transplant centre. Do not wait for late deterioration: encephalopathy accompanying acute liver injury should trigger transfer, and acetaminophen-associated disease can progress especially quickly. [1]
  • Monitor grade 2 or higher encephalopathy in intensive care. Intubate for airway protection with grade 3 or 4 encephalopathy; repeated neurological assessment is central to detecting progression. [1]
  • Reserve biopsy for selected diagnostic questions such as autoimmune hepatitis, infiltrative disease or malignancy. Routine biopsy otherwise lacks sufficient evidence; when biopsy is needed in acute liver failure, the guideline suggests a transjugular approach. [1]

Support organs without routine unproven interventions

  • For acute liver failure with grade 2 or higher encephalopathy, consider early continuous renal replacement therapy for hyperammonaemia even without conventional dialysis indications. This is conditional and based on very-low-quality evidence. [1]
  • There is no conclusive evidence for or against lactulose or rifaximin specifically for acute-liver-failure encephalopathy. Do not assume the evidence from cirrhosis establishes their benefit in this distinct condition. [1]
  • Routine invasive intracranial-pressure monitoring and routine hypothermia are not supported by conclusive evidence. Intracranial monitoring may be considered only in highly selected patients at centres with appropriate expertise. [1]
  • Do not correct coagulopathy routinely when there is neither active bleeding nor an impending high-risk procedure. INR is not an accurate bleeding-risk measure; viscoelastic tests may provide a more informative assessment. This transfusion recommendation is conditional with very-low-quality evidence. [1]
  • Assess for infection early because fever and other clinical signs may be absent, and obtain regular surveillance cultures although the optimal frequency is unknown. Do not give routine prophylactic antimicrobials; clinical deterioration may warrant empirical antibacterial and antifungal treatment. [1]
  • Start intravenous fluids for hypotension. Use norepinephrine first line when hypotension is fluid refractory; add vasopressin if norepinephrine is inadequate. The norepinephrine recommendation is strong, whereas adding vasopressin is conditional. [1]
  • Consider renal replacement early for acute kidney injury, metabolic or electrolyte abnormalities, or volume overload. When renal replacement is required, favor continuous treatment over intermittent haemodialysis; ammonia control can be a separate indication. [1]
  • Monitor and correct glucose, fluid and electrolyte abnormalities. Use enteral nutritional support when oral intake cannot resume within 5–7 days, provided feeding is feasible and safe; this summary does not establish a universal protein prescription. [1]

Begin time-sensitive cause-specific care

  • Start N-acetylcysteine promptly when acetaminophen toxicity is suspected, including when ingestion timing is unknown; treatment can begin while diagnostic results are awaited. Individualize duration using clinical and laboratory recovery rather than assuming a fixed course always suffices. [1]
  • For a known acetaminophen overdose within 4 hours, the source recommends single-dose activated charcoal, taking consciousness and aspiration risk into account. The nomogram is chiefly useful for a single timed ingestion and is less useful for repeated or sustained-release ingestion. [1]
  • Stop a suspected offending drug immediately in non-acetaminophen drug injury. The guideline supports intravenous NAC in non-acetaminophen acute liver failure, with a strong GRADE designation and moderate-quality evidence; supportive care and transplant assessment remain essential. [1]
  • For acute liver failure from HBV reactivation, start an entecavir- or tenofovir-based antiviral regimen. If herpes simplex infection is suspected, begin intravenous acyclovir early without waiting for confirmation; suspected zoster hepatitis also requires prompt treatment. [1]
  • For mushroom-associated acute liver failure, seek poison-centre guidance and initiate intravenous silibinin as soon as possible; intravenous penicillin G may be used if silibinin is unavailable. This is a conditional recommendation with very-low-quality evidence, not a complete poisoning regimen. [1]
  • Begin transplant evaluation during diagnostic work-up for suspected or confirmed Wilson-disease acute liver failure because effective definitive medical therapy is lacking. Acute severe autoimmune hepatitis that has progressed to liver failure likewise requires early transplant evaluation. [1]
  • Pregnancy-specific acute liver failure from HELLP syndrome or acute fatty liver of pregnancy requires urgent multidisciplinary care and prompt delivery when clinically feasible; evaluate for transplant if recovery does not follow delivery. In Budd–Chiari-associated failure, start heparin unless contraindicated, consider TIPS after anticoagulation failure, and evaluate nonresponders for transplant. [1]

Use prognosis to support specialist decisions

  • Use King’s College Criteria or MELD for prognostication. Meeting King’s College Criteria or MELD >25 identifies high risk of poor outcome in this guideline; neither replaces serial clinical assessment or the transplant team’s individualized candidacy decision. [1]
  • There is insufficient evidence for or against routine high-volume plasma exchange or artificial or bioartificial liver-support devices. These should not be presented as established substitutes for timely organ support and transplant-centre care. [1]

Limitations and use

  • This selected summary is not a complete intensive-care, toxicology or transplant-listing protocol. It omits detailed initial laboratory panels, drug infusion doses, cerebral-oedema rescue regimens and complete prognostic-score criteria.
  • The source contains narrative and key-concept statements with differing detail, particularly corticosteroid use in acute severe autoimmune hepatitis. Specialist decisions must distinguish acute severe hepatitis without encephalopathy from established acute liver failure; steroid treatment must not delay transplant evaluation.
  • Uncertain practices, including routine intracranial monitoring, hypothermia, liver-support devices and extrapolated encephalopathy drugs, are presented as evidence gaps rather than routine orders.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Liver: Acute Liver Failure

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ACG
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognize the syndrome and refer early
  • Support organs without routine unproven interventions
  • Begin time-sensitive cause-specific care
  • Use prognosis to support specialist decisions
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House